ViroPharma Incorporated Drug Appeal Seen Driving 50% Return: Real M&A

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ViroPharma Inc. (VPHM), the maker of drugs for rare diseases that rallied on optimism it will be the next biotechnology takeover target, could fetch a 50 percent premium in a deal. The stock already surged as much as 34 percent to a 13-year high after Bloomberg News reported ViroPharma is working with Goldman Sachs (GS) Group Inc. on a possible auction and attracted interest from suitors including European drugmakers Sanofi and Shire Plc (SHP), citing people familiar with the process. JMP Group Inc. said the $2.6 billion seller of a treatment for hereditary angioedema, an inflammatory condition, could fetch $60 a share, compared with $40 yesterday.

Help employers find you! Check out all the jobs and post your resume.

Back to news